Related Experiment Video
Updated: Mar 25, 2026
A Quantitative Detection Method for MicroRNAs in the Kidney of an Ischemic Kidney Injury Mouse Model
Published on: September 11, 2020
MicroRNA biomarkers in clinical renal disease: from diabetic nephropathy renal transplantation and beyond
Rounak Nassirpour1, Dominic Raj2, Raymond Townsend3
1Drug Safety, Pfizer Worldwide Research and Development, Andover, MA, USA.
Insights
MicroRNAs show promise as novel biomarkers for early diagnosis and monitoring of Chronic Kidney Disease (CKD). These molecules could improve upon current measures like eGFR and albuminuria for better CKD patient care.
Area of Science:
- Nephrology
- Molecular Biology
- Biomarker Discovery
Background:
- Chronic Kidney Disease (CKD) affects millions, increasing mortality and cardiovascular risks.
- Current diagnostic and prognostic tools (e.g., eGFR, proteinuria) have limitations in CKD care.
- Novel biomarkers are needed for early diagnosis, injury assessment, progression estimation, and therapy response evaluation in CKD.
Purpose of the Study:
- To review the potential of microRNAs (miRNAs) as biomarkers in Chronic Kidney Disease (CKD).
- To explore miRNA performance in diabetes-related nephropathy and kidney transplant recipients.
- To discuss challenges and future directions for miRNA clinical development in CKD.
Main Methods:
- Literature review focusing on microRNA research in kidney disease.
- Analysis of miRNA utility in specific CKD contexts like diabetic nephropathy and post-transplant complications.
- Evaluation of miRNAs as potential adjuncts or replacements for existing renal biomarkers.
Main Results:
- MicroRNAs (miRNAs) are small, non-coding RNAs with potential as diagnostic and prognostic markers in various diseases.
- Emerging evidence suggests miRNAs can serve as biomarkers for renal disease, including in diabetes and kidney transplantation.
- miRNAs may offer improved sensitivity and specificity over current markers like estimated glomerular filtration rate (eGFR) and albuminuria.
Conclusions:
- MicroRNAs represent a promising class of biomarkers for advancing Chronic Kidney Disease (CKD) diagnosis and management.
- Further research and clinical validation are necessary to overcome pitfalls and realize the full potential of miRNAs in nephrology.
- miRNAs could significantly enhance the clinical evaluation of kidney disease beyond current standard measures.
Abstract:
Chronic Kidney Disease (CKD) is a common health problem affecting 1 in 12 Americans. It is associated with elevated risks of mortality, cardiovascular disease, and high costs for the treatment of renal failure with dialysis or transplantation. Advances in CKD care are impeded by the lack of biomarkers for early diagnosis, assessment of the extent of tissue injury, estimation of disease progression, and evaluation of response to therapy. Such biomarkers should improve the performance of existing measures of renal functional impairment (estimated glomerular filtration rate, eGFR) or kidney damage (proteinuria). MicroRNAs (miRNAs) a class of small, non-coding RNAs that act as post-transcriptional repressors are gaining momentum as biomarkers in a number of disease areas. In this review, we examine the potential utility of miRNAs as promising biomarkers for renal disease. We explore the performance of miRNAs as biomarkers in two clinically important forms of CKD, diabetes and the nephropathy developing in kidney transplant recipients. Finally, we highlight the pitfalls and opportunities of miRNAs and provide a broad perspective for the future clinical development of miRNAs as biomarkers in CKD beyond the current gold standards of eGFR and albuminuria.
Related Concept Videos
01:25Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration